Relacorilant

Corcept Therapeutics has submitted a New Drug Application to the FDA for relacorilant, a selective cortisol modulator designed to treat patients with endogenous hypercortisolism (Cushing's syndrome).

Corcept Therapeutics' relacorilant demonstrates sustained improvements in cardiometabolic measures in patients with Cushing's syndrome over six years.

Relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel, demonstrates potential in treating platinum-resistant ovarian cancer.

Corcept Therapeutics' Phase III GRADIENT trial of relacorilant in Cushing's syndrome did not meet its primary endpoint of statistically significant improvement in systolic blood pressure.

The ROSELLA trial is evaluating relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel for platinum-resistant ovarian cancer.